-
Infliximab, a
chimeric monoclonal antibody, sold
under the
brand name
Remicade among others, is a
medication used to
treat a
number of
autoimmune diseases...
- not infectious.
Treatments may
include corticosteroids, ciclosporin,
infliximab, or canakinumab. The
disease was
identified in 1930. It
affects approximately...
- such as
infliximab from
binding antigen in a
laboratory test. Specifically,
neutralization occurs when the anti-drug
antibody binds to
infliximab's antigen...
- of a
monoclonal antibody to be
approved worldwide was a
biosimilar of
infliximab in the EU in 2013. On
March 6, 2015, the FDA
approved the
United States'...
- 1988, a
monoclonal antibody called infliximab was
discovered at New York University's
School of Medicine.
Infliximab works by
binding to TNF, stopping...
- manifestations. Anti-TNF
therapy such as
infliximab has
shown promise in
treating the
uveitis ****ociated with the disease.
Infliximab as well as
other anti-TNF therapies...
-
young males with
inflammatory bowel disease. TNF-α
Inhibitor treatments (
infliximab, adalimumab, certolizumab, natalizumab, and etanercept) are
thought to...
-
Inhibition of TNF
effects can be
achieved with a
monoclonal antibody such as
infliximab, adalimumab,
certolizumab pegol, and golimumab, or with a circulating...
-
binding protein is a
monoclonal antibody or a
circulating receptor such as
infliximab (Remicade),
etanercept (Enbrel), or
adalimumab (Humira) that
binds to...
- allergies,
azathioprine and antibodies,
including mepolizumab, omalizumab,
infliximab, and adalimumab. The word
enteritis (/ˌɛntəˈraɪtɪs/) uses
combining forms...
